Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that the Company’s Chairman, Cathal Friel, will be attending the HC Wainwright Global Investment Conference, which is taking place from 12-14 September at the Lotte New York Palace Hotel in New York City, NY, USA.
Poolbeg Pharma to attend HC Wainwright Global Investment Conference
- Written by: Amilia Stone
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma and HOOKIPA Pharma propose a new collaboration with Gilead Sciences set to invest up to $8.7495 million, pending further negotiations.
Los Consejos de Poolbeg Pharma y HOOKIPA Pharma anuncian el respaldo de Gilead para una posible oferta y la actualización de su recaudación de fondos.
Poolbeg Pharma and HOOKIPA Pharma confirm Gilead Sciences' support for participation in a $30 million+ private placement fundraise amid potential merger talks.
HOOKIPA Pharma and Poolbeg Pharma are exploring a potential all-share acquisition, aiming to create a powerful Nasdaq-listed biopharmaceutical entity.
Poolbeg Pharma unveils promising POLB 001 data at ASH Meeting, highlighting its potential as a CRS preventative therapy in cancer immunotherapies.
Poolbeg Pharma secures US patent approval for POLB 001, enhancing its IP portfolio and advancing treatments for severe influenza and cytokine storms.
